scholarly journals High dose intravenous steroid therapy for severe posterior segment uveitis in Behcet's disease

2002 ◽  
Vol 86 (5) ◽  
pp. 521-523 ◽  
Author(s):  
E Toker
Keyword(s):  
Behçet’S Disease ◽  
Steroid Therapy ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Posterior Segment ◽  
High Dose ◽  
Behcet's Disease ◽  
Intravenous Steroid

scholarly journals Recurrent Interstitial Pneumonitis in a Patient with Entero-Behçet’s Disease Initially Treated with Mesalazine

2016 ◽  
Vol 2016 ◽  
pp. 1-6
Author(s):  
Akihiro Nakamura ◽  
Tomoya Miyamura ◽  
Brian Wu ◽  
Eiichi Suematsu
Keyword(s):  
Behçet’S Disease ◽  
Steroid Therapy ◽  
Interstitial Pneumonitis ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Rare Condition ◽  
Oral Prednisolone ◽  
High Dose ◽  
Behcet's Disease ◽  
Pulmonary Infiltration

A 65-year-old man with entero-Behçet’s disease (BD) being treated with mesalazine was presented to our hospital complaining of dyspnea. Computed tomography (CT) of the chest showed ground-glass opacities and he was initially diagnosed with mesalazine-induced interstitial pneumonitis (IP). Besides the discontinuation of mesalazine, a high dose of oral prednisolone was administered and the patient seemed to recover. However, four months later, dyspnea recurred and repeated CT revealed more extensive pulmonary infiltration despite steroid therapy. After the exclusion of infections, we suspected either a recurrence of mesalazine-induced IP or BD-related IP as a clinical manifestation of BD. The patient was treated with intravenous methylprednisolone and cyclophosphamide, followed by orally administered azathioprine, based on the assumption of underlying vasculitis. Thereafter, his condition improved. BD-related IP is an extremely rare condition with limited reports in the literature. Mesalazine-induced IP is also uncommon but the prognosis is generally good after discontinuation of mesalazine with or without steroid therapy. We discuss an extremely rare case, especially focusing on BD-related IP and mesalazine-induced IP as a potential cause of recurrent IP in a patient with entero-BD.

scholarly journals AB0531 GOLIMUMAB IN THE TREATMENT OF SEVERE AND/OR REFRACTORY VASCULO-BEHÇET’S DISEASE: A SINGLE-CENTRE EXPERIENCE IN CHINA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1562.1-1563
Author(s):  
L. Sun ◽  
J. Liu ◽  
W. Zheng
Keyword(s):  
Aortic Regurgitation ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
High Dose ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Severe Aortic Regurgitation ◽  
Tnf Α

Background:Vascular involvement is one of the leading causes of mortality and morbidity in Behcet’s Disease (BD)1. Surgical treatments are difficult for Vaculo-BD (VBD) patients due to the high risk of serious postoperative complications without effective and promptly perioperative immunotherapy2, 3. Anti-tumor necrosis factor alpha (TNF-α) therapy has been reported as a potential treatment in severe VBD, e.g. infliximab (IFX) and adalimumab (ADA). However, only few case reports are available regarding the fully humanized monoclonal antibody to TNF-α, golimumab (GOL), in the management of VBD4.Objectives:The objective of this study was to report the efficacy and safety of GOL for the treatment of severe and/or refractory VBD.Methods:We retrospectively analyzed the efficacy and safety profile of patients with severe and/or refractory VBD treated with GOL in our medical center between 2018 to 2020.Results:Nine VBD patients (8 male and 1 female) were enrolled, with a mean age and median course of 37±8.6 years and 72 months (range 12 to 300), respectively. Cardiac involvements (severe aortic regurgitation secondary to BD) were presented in 7 patients, including 2 patients with post-operative paravalvular leakage (PVL) after aortic valve replacement surgery. Multiple vascular lesions were documented in the other 2 patients, including one patient with life-threatening multiple pulmonary aneurysms, pulmonary thromboembolism and recurrent deep vein thrombosis, and another patient with abdominal aortic pseudoaneurysm and multiple artery stenosis and occlusion. Prior to GOL therapy, all patients experienced disease progression despite high-dose glucocorticoids combined with multiple immunosuppressants. Moreover, seven patients required effective and fast control of inflammation and a decrease of glucocorticoid dose during the perioperative period. They were treated with GOL, 50mg every 4 weeks, in combination with background low-or medium-dose glucocorticoids and immunosuppressants, for a median of 6 (range 3-15) months. After a mean duration of follow-up of 10 (range 2-6) months, all patients achieved improvement both in clinical symptoms and serum inflammation markers. The ESR level [4.88±4.94 mm/h vs 31.13±31.78mm/h, P<0.01] and CRP level [1.9 (0.11-3.73)mg/L vs 24.3 (0.4-85.57)mg/L, P<0.01] significantly decreased. The dosage of glucocorticoid[10 (0-15) vs 40 (0-100)mg/d, P<0.01] effectively tapered, indicating a potential steroid-sparing effect. No newly-onset aneurysm and recurrent venous thrombosis were observed. Also, one patient had a marked reduction in size and number of pulmonary aneurysms. No post-operative PVL was observed in the five patients after Bentall operation with a median follow-up of 10 months. One patient with severe aortic regurgitation remained stable and without surgical intervention with the treatment of GOL for 16 months. No severe complication occurred in one patient after underwent endovascular repair of abdominal aorta for 8 months. GOL was well-tolerated, and no serious adverse event was observed.Conclusion:Our results suggested that GOL is safe and effective for the treatment of patients with severe and / or refractory VBD. Further controlled studies are warranted to confirm the therapeutic potential of GOL in VBD patients.Disclosure of Interests:None declared

scholarly journals High-Dose Cyclophosphamide Without Stem Cell Rescue for the Treatment of Refractory Behcet's Disease

2011 ◽  
Vol 41 (2) ◽  
pp. 301-304 ◽  
Author(s):  
Charles F. Henderson ◽  
Robert A. Brodsky ◽  
Richard J. Jones ◽  
Stuart M. Levine
Keyword(s):  
Stem Cell ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
High Dose ◽  
Behcet's Disease ◽  
Stem Cell Rescue

scholarly journals Behcet’s Disease with Intracardiac Thrombus Presenting with Fever of Unknown Etiology

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Sajal Ajmani ◽  
Durga Prasanna Misra ◽  
Deep Chandh Raja ◽  
Namita Mohindra ◽  
Vikas Agarwal
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Thrombus Formation ◽  
Young Male ◽  
Unknown Etiology ◽  
High Dose ◽  
Intracardiac Thrombus ◽  
High Grade Fever ◽  
Behcet's Disease

A young male was referred to us for evaluation of fever of unknown origin (FUO). He had history of recurrent painful oral ulcers for one year and moderate to high grade fever, pustulopapular rash, and recurrent genital ulcers for 6 months and hemoptysis for 3 days. He was detected to have intracardiac thrombi and pulmonary arterial thrombosis along with underlying Behcet’s disease (BD). Patient responded to high dose prednisolone (1 mg/Kg/day) along with monthly parenteral cyclophosphamide therapy. This case highlights the fact that BD is an important cause for pulmonary artery vasculitis with intracardiac thrombus formation, and such patients can present with FUO.

Behcet's disease with slowly enlarging midbrain mass on MRI: Resolution following steroid therapy

Neurology ◽  
1989 ◽  
Vol 39 (9) ◽  
pp. 1251-1251 ◽  
Author(s):  
A. G. Kermode ◽  
G. T. Plant ◽  
D. G. MacManus ◽  
B. E. Kendall ◽  
D.P.E. Kingsley ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Steroid Therapy ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease

C0118: Thrombophilic Mutations in Ocular Behçet’s Disease with Posterior Segment Involvement

2014 ◽  
Vol 133 ◽  
pp. S49
Author(s):  
A. Vayá Montaña ◽  
M. Suescun Giménez ◽  
E. España ◽  
F. España Furió ◽  
J.M. Ricart Vayá
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Posterior Segment ◽  
Behcet's Disease ◽  
Thrombophilic Mutations

scholarly journals Uveitis-induced Refractory Ocular Hypotony Managed with High-dose Latanoprost

2020 ◽  
Author(s):  
Fariba Ghassemi ◽  
Mohammad Reza Niyousha ◽  
Narges Hassanpoor ◽  
Hassan Khojasteh
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Silicone Oil ◽  
Behçet's Disease ◽  
Treatment Modalities ◽  
High Dose ◽  
Behcet's Disease ◽  
Multiple Treatment ◽  
Ocular Hypotony ◽  
History Of

Purpose: To report a case of refractory ocular hypotony due to chronic Behcet’s disease with good response to high-dose topical latanoprost. Case Report: We present a 26-year-old man with a known history of Behcet’s disease who developed decreasing vision and severe ocular hypotony that was refractory to multiple treatment modalities including subtenon triamcinolone acetonide, ibopamine, pars plana vitrectomy, and silicone oil injection. We decided to try high-dose topical latanoprost for the management of ocular hypotony based on recent reports. After six months, intraocular pressure (IOP) increased by 5 mm Hg, became stable at 7 mm Hg, and remained unchanged at month 24. Conclusion: High-dose topical latanoprost could lead to significant increase in IOP in uveitis-induced refractory ocular hypotony.

scholarly journals The Effectiveness of Intraocular Methotrexate in the Treatment of Posterior Uveitis in Behçet’s Disease Patients Compared to Retrobulbar Steroids Injection

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Hossam El Din Mohamed Khalil ◽  
Heba A. El Gendy ◽  
Hala Ahmed Raafat Youssef ◽  
Hazem Effat Haroun ◽  
Tamer Atef Gheita ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Posterior Uveitis ◽  
Posterior Segment ◽  
Treatment Modalities ◽  
Cross Sectional ◽  
Behcet's Disease ◽  
Group A ◽  
Group B

Aim of Work. To evaluate the efficacy of intravitreal methotrexate (MTX) compared to retrobulbar triamcinolone acetonide (TAA), in controlling posterior segment involvement and inducing remissions among Behçet’s disease (BD) patients.Study Design. This is a cross-sectional nonrandomized comparative study.Patients and Methods. 31 adult BD male patients with a mean disease duration of 5.45 years who presented with bilateral posterior segment involvement were included. Each patient received intravitreal injection of 400 μg/0.1 mL (MTX) for the right eye (Group A) and 1 mL of retrobulbar 40 mg/mL TAA for the left eye (Group B).Results. 90% of eyes showed complete improvement of anterior chamber reaction, whereas an improvement in vitreous activity in 77% with no significant differences between both groups (p≤0.1). BCVA improved in 77.4% eyes (Group A) compared to 87.1% (Group B) (p≤0.4). Relapses were noted in 11 eyes (35.5%), in group A, with the mean duration of remission being 19.1 weeks ± 2.13 compared to7.35±2.8in 20 eyes (64.5%) in group B (p≤0.1).Conclusion. No statistical differences were found between both treatment modalities; however, based on clinical observations, intravitreal MTX may ensure better control of inflammatory reaction and may encourage longer remission as compared to retrobulbar TAA in BD patients.

scholarly journals The role of intraocular methotrexate in the management of uveitis and posterior segment involvement in Behçet’s disease patients

2015 ◽  
Vol 37 (3) ◽  
pp. 113-118 ◽  
Author(s):  
Hossam Eldin M. Khalil ◽  
Hala Ahmed Raafat ◽  
Noha Ahmed Azab ◽  
Hazem E. Haroun ◽  
Heba A. Elgendi
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Posterior Segment ◽  
Behcet's Disease
Sign in / Sign up

Export Citation Format

Share Document